EUCTR2005-002492-32-IT进行中（未招募）不适用
A 52 week treatment, multi center, randomized, double blind, palcebo controlled, parallel group study to assess the efficacy, safety and tolerability of indacaterol 200 400 mcg od in patients with persistent asthma using formoterol 12 mcg bid as an active control - ND
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 750
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •. Male and female adults/adolescents aged 8805; 12 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure. In the case of patients below the legal age of consent, the Informed Consent Form must also be signed by the patient s parent / guardian. 2. Patients with mild to severe persistent asthma, diagnosed according to GINA guidelines Updated 2004 and who additionally meet the following criteria a Patients who have used treatment with a bronchodilator, either regularly or on-demand, and who have used a daily dose of at least 200 g BDP or equivalent up to the maximum daily dose as recommended in the package leaflet for at least one month prior to Visit 1. b Patients whose FEV1 at Visit 1 is 8805;50 , of the predicted normal value for the patient. This criterion for FEV1 is to be demonstrated after an appropriate washout period for all bronchodilators e.g. at least six hours for short-acting bronchodilators such as albuterol and 48 hours for long acting bronchodilators such as formoterol prior to the evaluation. c Patients who demonstrate a 15 increase in FEV1, over their pre-bronchodilator value within 30 minutes after inhaling a total of 200/180 g salbutamol/albuterol via MDI i.e., two inhalations , demonstrated after an appropriate washout period for all bronchodilators e.g. at least six hours for short-acting bronchodilators such as albuterol and 48 hours for long acting bronchodilators such as formoterol prior to the evaluation. The administration of albuterol for the reversibility test is to be within 30 minutes after a pre bronchodilator spirometry. Reversibility has to be demonstrated either at Visit 1 or between visits 1 and 2, in order for patients to be included in the trial. d Patients experiencing symptoms on a weekly basis as recorded in their diary during the run-in period and having a minimum symptom score of 1 on at least two days per week over the two week run-in period
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Pregnant or nursing lactating women, women of child-bearing potential, UNLESS they are post-menopausal or using an acceptable method of contraception For females aged 12 to 17 years acceptable methods of contraception may include total abstinence at the discretion of the investigator. 2. Patients who have used tobacco products within the 12 month period prior to Visit 1, or who have a smoking history of greater than 10 pack years. 3. Patients who suffer from COPD as diagnosed by the GOLD guidelines 2004 . 4. Patients who have had emergency room treatment for an acute asthma attack in the 6 weeks prior to Visit 1 or who have been hospitalized for an acute asthma attack in the 6 months prior to Visit 1, or at any time between Visit 1 and Visit 2. 5. Patients who have had a respiratory tract infection within 6-weeks prior to Visit 1. Patients who develop a respiratory tract infection between Visit 1 and 2 must discontinue from the trial, but will be permitted to re-enroll at a later date at least 6-weeks after the resolution of the respiratory tract infection . 6. Patients with diabetes Type I or uncontrolled diabetes Type II including patients with a history of blood glucose levels consistently outside the normal range or HbA1C 8.0 measured at Visit 1. 7. Patients who, in the judgment of the investigator or the responsible Novartis personnel, have a clinically relevant laboratory abnormality or a clinically significant condition such as but not limited to unstable ischemic heart disease, arrhythmia, uncontrolled hypertension, uncontrolled hypo- and hyperthyroidism, hypokalemia, hyperadrenergic state, that might compromise patient safety or compliance, interfere with evaluation, or preclude completion of the study. 8. Any patient with active cancer or a history of cancer with less than 5 years disease free survival time whether or not there is evidence of local recurrence or metastases . Localized basal cell carcinoma without metastases of the skin is acceptable. 9. Patients with a history of long QT syndrome, or whose QTc interval Bazett s formula measured at Visits 1 or 2 is prolonged 450 ms males; 470 ms females . 10. Patients with a history of hypersensitivity to any of the study drugs or to drugs with similar chemical structures including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof. 12. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives prior to Visit 1, whichever is longer 13. Patients who have had live attenuated vaccinations within 30 days prior to Visit 1 or during the run-in period influenza vaccination is acceptable provided it is not administered within 48 hours prior to Visit 1 or 2 . 14. Patients unable or unwilling to complete a patient daily diary. 15. Treatments for asthma and allied conditions the following medications must not be used prior to Visit 1 for at least the minimum washout period specified below or at any time during the study a The long acting anti-cholinergic agent tiotropium bromide 7 days. b Short acting anti-cholinergics 8 h c Fixed combinations of 61538;2-agonists and inhaled corticosteroids 48 h patients taking fixed dose combination therapy must switch to an equivalent inhaled corticosteroid as monotherapy plus salbutamol/albuterol as rescue therapy d Long-acting 61538;2-agonists other than as prescribed in the study 48 h e Short acting 61538;2-agonists other than
研究者
相似试验
进行中（未招募）
不适用
A 52-week treatment, multi-center, randomized, double-blind,parallel-group, active controlled study to evaluate the effect ofQVA149 (110/50 µg o.d.) vs NVA237 (50 µg o.d.) and open-labeltiotropium (18 µg o.d.) on COPD exacerbations in patients withsevere to very severe chronic obstructive pulmonary disease(COPD)Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 12.1Level: LLTClassification code 10010952Term: COPDMedDRA version: 12.1Level: LLTClassification code 10010953Term: COPD exacerbationEUCTR2009-013256-69-NLovartis Pharma AG2,200
进行中（未招募）
不适用
A 52-week treatment, multi-center, randomized, double-blind,parallel-group, active controlled study to evaluate the effect ofQVA149 (110/50 µg o.d.) vs NVA237 (50 µg o.d.) and open-labeltiotropium (18 µg o.d.) on COPD exacerbations in patients withsevere to very severe chronic obstructive pulmonary disease(COPD)EUCTR2009-013256-69-GRovartis Pharma AG2,200
进行中（未招募）
不适用
Study of efficacy and safety of QVA149 compared to salmeterol/fluticasone active comparator in patients with COPD.subjects with moderate to very severe COPDMedDRA version: 15.1Level: LLTClassification code 10010953Term: COPD exacerbationSystem Organ Class: 100000004855EUCTR2012-004966-16-ITovartis Farma3,332
进行中（未招募）
1 期
Study of efficacy and safety of QVA149 compared to salmeterol/fluticasone active comparator in patients with COPD.subjects with moderate to very severe COPDMedDRA version: 17.0Level: LLTClassification code 10010953Term: COPD exacerbationSystem Organ Class: 100000004855EUCTR2012-004966-16-PTovartis Pharma AG3,332
已完成
3 期
Effect of QVA149 Versus NVA237 on Chronic Obstructive Pulmonary Disorder (COPD) ExacerbationsCTRI/2010/091/000665ovartis Healthcare Pvt Ltd2,200